Dermatology Drugs Market Characteristics
The dermatology drugs market consists of sales of dermatology drugs and related by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes establishments that produce drugs to treat diseases such as rosacea, dermatitis, hyperhidrosis, androgenic alopecia, acne, microbial infections and other skin disorders.
Competitive Landscape of the Dermatology Drugs Market
Major players in the global Dermatology drugs market include Johnson & Johnson, Allergan Plc, Galderma S.A, Novartis AG, GlaxoSmithKline Plc
Dermatology Drugs Market Size
The dermatology drugs market size is expected to reach $40 billion by 2022, significantly growing at a CAGR of around 5% during the forecast period. The growth in the Dermatology drugs market is due to increase in the number of indications treated by topical drugs coupled with increase in acne and rosacea patients will drive the market for dermatology drugs.
However, the market for Dermatology drugs is expected to face certain restraints from several factors such as rising government regulations and shifting trends towards Ayurvedic medicines.
Dermatology Drugs Market Segmentation
The global dermatology drugs market is further segmented based on type and geography.
By Type - The dermatology drugs market is segmented into snack and non-alcoholic beverage bars, drinking places (alcoholic beverages) among these segments, the snack and non-alcoholic beverage bars market accounts for the largest share in the global Dermatology drugs market.
By Geography - The global dermatology drugs is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, Asia Pacific was the largest region in the global dermatology drugs market.
Trends in the Dermatology Drugs Market
Pharmaceutical companies are offering new drugs referred to as immune modulators for the treatment of skin diseases such as eczema. Eczema is a chronic skin condition caused by the lack of skin proteins that results in inflammation and irritation in the skin. These drugs are used to externally treat the skin without changing the immune system of the body. In addition, unlike topical steroids, these new medications do not cause thinning of the skin and breaking of superficial blood vessels. Tacrolimus (Protopic) and Pimecrolimus (Elidel) are major drugs available for the treatment of eczema.
Potential Opportunities in the Dermatology Drugs Market
Due to approval of large number of drugs approved by FDA and other regulatory bodies to cure increased skin conditions and disorders the scope and potential for the global dermatology drugs market is expected to significantly rise in the forecast period.